Close Menu

NEW YORK – Fluidigm said on Wednesday that it has completed the acquisition of InstruNor, a privately held, Oslo-based provider of integrated sample preparation systems for flow and mass cytometry.

Fluidigm purchased all outstanding shares of InstruNor for approximately $7.2 million, including $5.2 million in cash and approximately $2 million in stock.

InstruNor will become a part of Fluidigm's mass cytometry business, and Fluidigm said it expects the transaction to be accretive to earnings in 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.